Drug Profile
Sufentanil - Orexo
Alternative Names: OX27Latest Information Update: 06 Nov 2021
Price :
$50
*
At a glance
- Originator Orexo
- Class Amides; General anaesthetics; Opioid analgesics; Piperidines; Small molecules; Thiophenes
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer-pain in Sweden (Sublingual, Tablet)
- 21 Dec 2011 Orexo completes a pharmacokinetic study of OX 27 in healthy volunteers in Sweden
- 14 Jun 2011 Final pharmacokinetics data from a phase I trial in Cancer pain released by Orexo